Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Other Accumulated Expenses (2022 - 2025)

BioXcel Therapeutics has reported Other Accumulated Expenses over the past 4 years, most recently at $622000.0 for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $622000.0 for Q4 2025, up 93.17% from a year ago — trailing twelve months through Dec 2025 was $622000.0 (up 93.17% YoY), and the annual figure for FY2025 was $622000.0, up 93.17%.
  • Other Accumulated Expenses for Q4 2025 was $622000.0 at BioXcel Therapeutics, up from $450000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for BTAI hit a ceiling of $820000.0 in Q4 2022 and a floor of $152000.0 in Q1 2022.
  • Median Other Accumulated Expenses over the past 4 years was $352000.0 (2024), compared with a mean of $393500.0.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 78.41% in 2023 and later surged 93.17% in 2025.
  • BioXcel Therapeutics' Other Accumulated Expenses stood at $820000.0 in 2022, then crashed by 78.41% to $177000.0 in 2023, then surged by 81.92% to $322000.0 in 2024, then surged by 93.17% to $622000.0 in 2025.
  • The last three reported values for Other Accumulated Expenses were $622000.0 (Q4 2025), $450000.0 (Q3 2025), and $366000.0 (Q2 2025) per Business Quant data.